Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
$GLUE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
142
ISIN
US61225M1027
Website
GLUE Metrics
BasicAdvanced
$363M
76.14
$0.08
1.41
-
Price and volume
Market cap
$363M
Beta
1.41
52-week high
$10.11
52-week low
$3.50
Average daily volume
426K
Financial strength
Current ratio
5.611
Quick ratio
5.53
Long term debt to equity
13.81
Total debt to equity
15.214
Profitability
EBITDA (TTM)
6.143
Gross margin (TTM)
29.23%
Net profit margin (TTM)
3.86%
Operating margin (TTM)
-1.33%
Effective tax rate (TTM)
34.97%
Revenue per employee (TTM)
$1,120,000
Management effectiveness
Return on assets (TTM)
-0.40%
Return on equity (TTM)
2.88%
Valuation
Price to earnings (TTM)
76.144
Price to revenue (TTM)
2.938
Price to book
1.32
Price to tangible book (TTM)
1.32
Price to free cash flow (TTM)
15.372
Free cash flow yield (TTM)
6.51%
Free cash flow per share (TTM)
38.38%
Growth
Revenue change (TTM)
14,889.38%
Earnings per share change (TTM)
-103.10%
3-year earnings per share growth (CAGR)
-68.00%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
Bulls say / Bears say
Monte Rosa Therapeutics secured a global licensing agreement with Novartis, including a $150 million upfront payment and potential milestones up to $2.1 billion, significantly enhancing its financial position and validating its molecular glue degrader technology. (stocktwits.com)
The company's MRT-6160, targeting VAV1 for immune-mediated conditions, demonstrated promising preclinical results, leading to a strategic partnership with Novartis to advance its development. (benzinga.com)
Monte Rosa's collaboration with Roche to develop molecular glue degraders for cancer and neurological diseases, with an upfront payment of $50 million and potential milestones exceeding $2 billion, underscores strong industry confidence in its platform. (benzinga.com)
Despite significant partnerships, Monte Rosa reported a net loss of $72.7 million for the year ended December 31, 2024, indicating ongoing financial challenges. (monterosatx.com)
The company's cash position decreased from $377 million at the end of 2024 to $331 million by March 31, 2025, reflecting substantial cash burn and operational expenses. (stocktitan.net)
Monte Rosa's reliance on milestone payments from partnerships introduces revenue uncertainty, as these payments are contingent upon successful development and regulatory approvals. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 14 Jul 2025.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
GLUE News
AllArticlesVideos
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
GlobeNewsWire·2 weeks ago
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewsWire·1 month ago
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $363M as of July 18, 2025.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 76.14 as of July 18, 2025.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.